Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study

Paul M Palevsky, Theresa Z O'Connor, Glenn M Chertow, Susan T Crowley, Jane Hongyuan Zhang, John A Kellum, US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network, Paul M Palevsky, Theresa Z O'Connor, Glenn M Chertow, Susan T Crowley, Jane Hongyuan Zhang, John A Kellum, US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network

Abstract

Determination of the optimal dose of renal replacement therapy in critically ill patients with acute kidney injury has been controversial. Questions have recently been raised regarding the design and execution of the US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) Study, which demonstrated no improvement in 60-day all-cause mortality with more intensive management of renal replacement therapy. In the present article we present our rationale for these aspects of the design and conduct of the study, including our use of both intermittent and continuous modalities of renal support, our approach to initiation of study therapy and the volume management during study therapy. In addition, the article presents data on hypotension during therapy and recovery of kidney function in the perspective of other studies of renal support in acute kidney injury. Finally, we address the implications of the ATN Study results for clinical practice from the perspective of the study investigators.

Figures

Figure 1
Figure 1
All-cause mortality at 60 days as a function of days managed using intermittent hemodialysis. The time in the intermittent hemodialysis (IHD) phase was defined as the number of days from the first IHD treatment or from the first day after continuous renal replacement therapy (CRRT) or sustained low-efficiency dialysis (SLED) was discontinued until the last day of IHD treatment, the last day before initiation of CRRT or SLED, or the discontinuation of study therapy. Days with IHD and with either CRRT or SLED were counted as in the IHD phase. The percentage of days managed using IHD was calculated by dividing the number of days in the IHD phase by the total number of days of study therapy.

References

    1. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta RL, Palevsky PM. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol. 2008;3:869–875. doi: 10.2215/CJN.04821107.
    1. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int. 2002;62:1855–1863. doi: 10.1046/j.1523-1755.2002.00613.x.
    1. Palevsky PM. Clinical review: timing and dose of continuous renal replacement therapy in acute kidney injury. Crit Care. 2007;11:232. doi: 10.1186/cc6121.
    1. Ronco C, Ricci Z, Bellomo R. Current worldwide practice of dialysis dose prescription in acute renal failure. Curr Opin Crit Care. 2006;12:551–556. doi: 10.1097/01.ccx.0000247447.17124.05.
    1. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. for the VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20. doi: 10.1056/NEJMoa0802639.
    1. Ronco C, Cruz D, van Straaten HO, Honore P, House A, Bin D, Gibney N. Dialysis dose in acute kidney injury: no time for therapeutic nihilism – a critical appraisal of the Acute Renal Failure Trial Network study. Crit Care. 2008;12:308. doi: 10.1186/cc7016.
    1. Ronco C, Honore P. Renal support in critically ill patients with acute kidney injury [letter] N Engl J Med. 2008;359:1959. doi: 10.1056/NEJMc081598. author reply 1961–1962.
    1. Bouchard J, Macedo E, Mehta RL. Renal support in critically ill patients with acute kidney injury [letter] N Engl J Med. 2008;359:1959–1960. doi: 10.1056/NEJMc081598. author reply 1961–1962.
    1. Maynar-Moliner J, Sanchez-Izquierdo-Riera JA, Herrera-Gutierrez M. Renal support in critically ill patients with acute kidney injury [letter] N Engl J Med. 2008;359:1960. author reply 1961–1962.
    1. Bagshaw SM, Gibney N. Renal support in critically ill patients with acute kidney injury [letter] N Engl J Med. 2008;359:1960–1961. author reply 1961–1962.
    1. Uchino S, Bell M, Bellomo R. Renal support in critically ill patients with acute kidney injury [letter] N Engl J Med. 2008;359:1961. author reply 1961–1962.
    1. Palevsky PM, O'Connor T, Zhang JH, Star RA, Smith MW. Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clin Trials. 2005;2:423–435. doi: 10.1191/1740774505cn116oa.
    1. Overberger P, Pesacreta M, Palevsky PM. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol. 2007;2:623–630. doi: 10.2215/CJN.00780207.
    1. Keshaviah PR, Nolph KD, Van Stone JC. The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int. 1989;9:257–260.
    1. Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant. 1996;11:1574–1581.
    1. Clark WR, Mueller BA, Kraus MA, Macias WL. Dialysis prescription and kinetics in acute renal failure. Adv Ren Replace Ther. 1997;4(2 Suppl 1):64–71.
    1. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant. 1998;13(Suppl 6):10–14. doi: 10.1093/ndt/13.suppl_6.10.
    1. Gotch FA, Sargent JA, Keen ML. Whither goest Kt/V? Kidney Int Suppl. 2000;76:S3–S18. doi: 10.1046/j.1523-1755.2000.07602.x.
    1. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30. doi: 10.1016/S0140-6736(00)02430-2.
    1. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T, Martin PY. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006;70:1312–1317. doi: 10.1038/sj.ki.5001705.
    1. Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915–919. doi: 10.2215/CJN.01430406.
    1. Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, Pallot JL, Chiche JD, Taupin P, Landais P, Dhainaut J-F. for the Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006;368:379–385. doi: 10.1016/S0140-6736(06)69111-3.
    1. Crowley ST, Chertow GM, Vitale J, O'Connor T, Zhang J, Schein RM, Choudhury D, Finkel K, Vijayan A, Paganini E, Palevsky PM. for the VA/NIH Acute Renal Failure Trial Network Study Group. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clin J Am Soc Nephrol. 2008;3:955–961. doi: 10.2215/CJN.05621207.
    1. Troyanov S, Cardinal J, Geadah D, Parent D, Courteau S, Caron S, Leblanc M. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant. 2003;18:961–966. doi: 10.1093/ndt/gfg055.
    1. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA. 2008;299:793–805. doi: 10.1001/jama.299.7.793.
    1. Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, Lemaire F, Brochard L. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med. 2000;162:197–202.
    1. Palevsky PM, Franchini R, O'Connor TZ, Zhang JH. Recovery of kidney function in critically ill patients with acute kidney injury treated with intensive versus less intensive renal replacement therapy [abstract] J Am Soc Nephrol. 2008;19:790A.
    1. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008;19:1233–1238. doi: 10.1681/ASN.2007111173.
    1. Uchino S, Bellomo R, Kellum JA, Morimatsu H, Morgera S, Schetz MR, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-Van Straaten HM, Ronco C. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators Writing Committee. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30:281–292.
    1. Venkataraman R, Kellum JA, Palevsky P. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. J Crit Care. 2002;17:246–250. doi: 10.1053/jcrc.2002.36757.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe